Introduction to CSNK1A1P1 (G161635)

Target Name: CSNK1A1P1

NCBI ID: G161635

CSNK1A1P1

Other Name(s): Casein kinase 1 alpha 1 pseudogene 1 | casein kinase 1 alpha 1 pseudogene 1 | CSNK1A1P

Introduction to CSNK1A1P1
CSNK1A1P1, also known as Casein Kinase 1 Alpha Interacting Protein 1, is a novel drug target (or biomarker) that has gained significant attention in recent years due to its involvement in multiple biological processes. This article delves into the role of CSNK1A1P1 and its potential implications as a therapeutic target or biomarker in various diseases.

What is CSNK1A1P1?
CSNK1A1P1 is an RNA gene that encodes for a protein called Casein Kinase 1 Alpha Interacting Protein 1. It is located on human chromosome 1p36.23 and is primarily expressed in the brain, with lower levels of expression observed in other tissues such as the heart, liver, and lung.

The Role of CSNK1A1P1 in Disease:
Researchers have discovered that CSNK1A1P1 plays a critical role in various disease processes, making it a potential target for drug development or a valuable biomarker for disease diagnosis and prognosis.

1. Cancer:
CSNK1A1P1 has been implicated in the development and progression of several types of cancer. Studies have shown that it is overexpressed in breast cancer, gastric cancer, and hepatocellular carcinoma. The upregulation of CSNK1A1P1 is associated with increased cell proliferation, migration, invasion, and resistance to chemotherapy. Inhibition of CSNK1A1P1 has been shown to suppress tumor growth and enhance the sensitivity of cancer cells to chemotherapy, highlighting its potential as a therapeutic target in cancer treatment.

2. Neurodegenerative Disorders:
CSNK1A1P1 has also been implicated in neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease. Research has shown that CSNK1A1P1 interacts with key proteins involved in the formation of neurofibrillary tangles and amyloid plaques, which are pathological hallmarks of Alzheimer's disease. Inhibition of CSNK1A1P1 has shown promising results in reducing the accumulation of toxic proteins and ameliorating cognitive deficits in preclinical models of Alzheimer's disease. Similarly, targeting CSNK1A1P1 has shown potential in mitigating motor dysfunction and dopaminergic neuron loss in Parkinson's disease models.

3. Cardiovascular Disease:
CSNK1A1P1 has emerged as a key regulator of cardiovascular function. Studies have found that CSNK1A1P1 is involved in the regulation of cardiac contractility, heart rate, and vascular tone. Dysregulation of CSNK1A1P1 expression or activity has been associated with the development of cardiac arrhythmias, heart failure, and hypertension. Therefore, CSNK1A1P1 may serve as an attractive target for the development of novel cardiovascular therapeutics.

4. Metabolic Disorders:
CSNK1A1P1 has also been linked to metabolic disorders such as obesity and diabetes. Studies have shown that altered CSNK1A1P1 expression in adipose tissue affects adipocyte differentiation, insulin sensitivity, and glucose metabolism. Targeting CSNK1A1P1 has shown potential in improving adipose tissue functionality, decreasing insulin resistance, and reducing obesity-associated inflammation.

CSNK1A1P1 as a Therapeutic Target:
The diverse roles of CSNK1A1P1 in various diseases make it an attractive target for therapeutic intervention. However, further research is required to determine the precise mechanisms of action and develop specific inhibitors or modulators that selectively target CSNK1A1P1 without affecting closely related proteins. Additionally, clinical trials are needed to evaluate the safety and efficacy of CSNK1A1P1-targeted therapies in humans.

CSNK1A1P1 as a Biomarker:
In addition to its potential therapeutic applications, CSNK1A1P1 also holds promise as a biomarker for disease diagnosis, prognosis, and treatment response. Its differential expression levels in diseased tissues compared to healthy tissues make it useful for early detection and monitoring of disease progression. Furthermore, CSNK1A1P1 expression patterns may help stratify patients into different subgroups based on disease severity or treatment response, allowing for personalized medicine approaches.

Conclusion:
CSNK1A1P1 has emerged as a versatile drug target and a valuable biomarker in a wide range of diseases, including cancer, neurodegenerative disorders, cardiovascular disease, and metabolic disorders. Its diverse roles in disease pathogenesis highlight the need for further research to fully elucidate its mechanisms of action and develop targeted therapies. Moreover, the potential of CSNK1A1P1 as a biomarker opens up new avenues for early diagnosis, prognosis, and personalized treatment strategies. With ongoing advancements, CSNK1A1P1 has the potential to significantly impact disease management and improve patient outcomes.

Protein Name: Casein Kinase 1 Alpha 1 Pseudogene 1

The "CSNK1A1P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CSNK1A1P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets